Efficacy and safety of sofosbuvir-containing regimens in chronic hepatitis C patients with genotype 2 and 3: a comprehensive analysis of 18 randomized controlled trials.

Abstract

BACKGROUND AND AIM:

Sofosbuvir is a hepatitis C virus (HCV) NS5B polymerase inhibitor. The objective of this study was to explore the efficacy and safety of sofosbuvir for HCV genotype (GT) 2 and 3 infected patients.

METHOD:

We searched randomized controlled trials (RCTs) which analyzed the efficacy and safety of sofosbuvir-containing regimens for HCV GT 2/3 infected patients and collected data. The endpoints were sustained virological response 12- and 24-weeks after the cessation of therapy (SVR12 and SVR24), the adverse events (AEs) and the severe adverse events (SAEs).

RESULTS:

Eighteen trials comprising 2,975 HCV GT 2/3 infected patients were included. The pooled estimate SVR12, SVR24, AEs and SAEs rates were 84.6% (95% CI: 83.2-86.0), 83.7% (95% CI: 82.0-85.2), 83.8 (95% CI: 82.3-85.3) and 3.9 (95% CI: 3.2-4.8). The SVR12 rate of sofosbuvir-containing regimens for HCV GT 2 infection was higher than that for HCV GT 3 infection (95.7% vs. 80.8%). The sofosbuvir combined with velpatasvir (with or without ribavirin) regimen presented a higher SVR12 rate and lower AEs rate than the sofosbuvir combined with ribavirin (with or without peg-IFN) regimen (94.9% vs. 80.7% for SVR12 rate; 69.3% vs. 87.7% for AEs rate).

CONCLUSIONS:

The sofosbuvir-containing regimens in patients with HCV GT 2 infection have better efficacy than in patients with HCV GT 3 infection.

• Authors: Haozhi Fan, Peng Huang, Ting Tian, Jingjing Wu, Xueshan Xia, Yue Feng, Jie Wang, Rongbin Yu, Yun Zhang, Ming Yue
• Journal: Journal of gastrointestinal and liver diseases : JGLD (J Gastrointestin Liver Dis) Vol. 27 Issue 2 Pg. 159-168 (Jun 2018) ISSN: 1842-1121 [Electronic] Romania
• PMID: 29922761 (Publication Type: Meta-Analysis)

Chemical References

• Antiviral Agents
• Sofosbuvir

Topics

• Antiviral Agents (adverse effects, pharmacology, therapeutic use)
• Drug Therapy, Combination
• Genotype
• Hepacivirus (drug effects, genetics)
• Hepatitis C, Chronic (drug therapy, virology)
• Humans
• Randomized Controlled Trials as Topic
• Sofosbuvir (adverse effects, pharmacology, therapeutic use)
• Sustained Virologic Response